AC Immune (NASDAQ:ACIU) Trading Down 3.7% - Here's What Happened

Key Points

• AC Immune's stock (NASDAQ:ACIU) fell 3.7% to $2.07 on Monday, with trading volume down by 41% compared to its average session.
• Brokerages have mixed opinions; while HC Wainwright cut the target price from $16.00 to $12.00, Wall Street Zen upgraded their rating from "hold" to "buy".
• The company reported a loss of ($0.25) earnings per share, falling short of the consensus estimate of ($0.20), and forecasts a negative EPS of -0.62 for the current fiscal year.

AC Immune (NASDAQ:ACIU - Get Free Report) fell 3.7% during mid-day trading on Monday . The stock traded as low as $2.07 and last traded at $2.07. 74,122 shares changed hands during trading, a decline of 41% from the average session volume of 124,793 shares. The stock had previously closed at $2.15.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of AC Immune from a "hold" rating to a "buy" rating in a report on Tuesday, May 13th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $12.00.

AC Immune Stock Down 0.5%

The company's 50-day simple moving average is $2.13 and its 200 day simple moving average is $2.01. The company has a market capitalization of $204.84 million, a P/E ratio of -3.52 and a beta of 1.65.

AC Immune (NASDAQ:ACIU - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.05). The business had revenue of $1.65 million during the quarter, compared to analyst estimates of $1.98 million. AC Immune had a negative net margin of 174.94% and a negative return on equity of 49.35%. As a group, equities research analysts forecast that AC Immune will post -0.62 earnings per share for the current year.

Hedge Funds Weigh In On AC Immune

A number of institutional investors have recently modified their holdings of ACIU. Geode Capital Management LLC boosted its holdings in shares of AC Immune by 9.9% during the 4th quarter. Geode Capital Management LLC now owns 64,090 shares of the company's stock worth $173,000 after buying an additional 5,794 shares during the period. Two Sigma Advisers LP bought a new stake in AC Immune during the fourth quarter valued at about $36,000. Boothbay Fund Management LLC bought a new stake in AC Immune during the fourth quarter valued at about $38,000. Jane Street Group LLC acquired a new stake in shares of AC Immune in the fourth quarter valued at about $66,000. Finally, Sei Investments Co. bought a new position in shares of AC Immune in the second quarter worth about $51,000. Institutional investors own 51.36% of the company's stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.